Lara D. Veeken,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 17, 2024
Abstract
Objectives
To
investigate
the
association
between
risk
of
different
co-morbidities
and
diagnosis
rheumatoid
arthritis
(RA)
using
a
temporal
approach.
Methods
Retrospective,
case-control
study.
Data
were
extracted
from
all
healthcare
claims
for
Poland
2011-2021.
Prevalent
RA(n
=
262
265)
patients
examined
to
evaluate
morbidity
patterns.
Incident
15
879)
age-,
sex-
region-matched
controls
sampled
1:10
general
population
(GP).
Exposure
was
new-onset
RA
identified
by
interspaced,
repeat
prescription.
Follow-up
performed
in
bidirectional,
five-year
timeframe
diagnosis(Dx).
Results
is
associated
with
enhanced
multiple
organ
system
disorders
both
pre-
post-Dx,
especially
hematologic
(IRR
1.80,
95%
CI
1.58,
2.05),
pulmonary
1.57,
1.53,
1.62),
gastrointestinal
1.46,
1.60),
cardiovascular
1.25,
1.22,
1.27)
conditions.
appears
strongly
interstitial
lung
disease
(pre-Dx
IRR
2.97,
2.20,
4.02;
post-Dx
4.66,
3.91,
5.56)
inflammatory
bowel
1.61,
2.07;
2.12,
1.70,
2.63).
Enhanced
thyroid
cancer
1.29,
1.00,
1.66)
lymphoma
1.50,
1.20,
1.88)
observed,
contrast
reduced
colon
0.77,
0.62,
0.94).
Conclusion
comorbidities
observed
post-RA
Dx,
varying
patterns
across
systems.
These
data
highlight
multisystem
nature
warrant
research
into
causal,
bidirectional
relationships.
The Journal of Rheumatology,
Journal Year:
2025,
Volume and Issue:
unknown, P. jrheum.2024 - 0545
Published: Jan. 15, 2025
In
recent
years,
the
outcomes
for
rheumatoid
arthritis
(RA)
have
improved
dramatically,
thanks
to
availability
of
biologic
disease-modifying
antirheumatic
drugs
(bDMARDs)
and
treat-to-target
strategies.1
Further,
earlier
initiation
therapies
results
in
better
tighter
control
disease,
since
prompt
treatment
induces
a
deeper
modulation
less
mature
more
reversible
inflammatory
process.1
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
16
Published: Feb. 6, 2025
Circulating
regulatory
T
cells
(Tregs)
are
closely
related
to
immune
tolerance
and
maintenance
of
homeostasis.
Perhaps,
there
is
a
unique
cell
phenotype
for
difficult-to-treat
rheumatoid
arthritis
(D2T
RA).
Low-dose
interleukin-2
(IL-2)
has
been
considered
the
treatment
autoimmune
diseases.
This
study
focused
on
uniqueness
D2T
RA
lymphocyte
subsets
feasibility
low-dose
IL-2
therapy.
Participants
included
1,042
patients
who
were
divided
into
three
groups
according
presence
or
absence
their
response
in
last
6
months-new
group,
treated
group-and
339
healthy
controls
(HCs).
A
total
381
patients-107,
151,
123
each
experimental
groups-received
[0.5
million
international
units
(MIU)
per
day,
subcutaneous
injection
from
day
1
5].
The
absolute
numbers
peripheral
blood
detected
by
flow
cytometry
(FCM)
serum
cytokine
levels
bead
array
(CBA).
number
T,
CD4+
Treg
group
was
lower
than
that
HC,
new,
groups.
Compared
with
HC
new
ratio
Th17/Treg
increased.
treated,
had
higher
HC.
negatively
correlated
disease
activity
index.
could
be
increased
therapy
without
any
side
effects.
lymphocytes
reduced,
especially
cells,
resulting
shift
balance
effector
cells/Treg
toward
which
ameliorated
obvious
Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
17(4), P. 474 - 474
Published: April 5, 2025
Background:
Rheumatoid
arthritis
is
a
chronic
autoimmune
disease
that
leads
to
severe
disability
and
requires
improved
therapeutic
strategies
optimize
anti-inflammatory
treatment.
This
study
aimed
address
this
challenge
by
developing
characterizing
an
extended-release
polymer
matrix
tablet
containing
ketoprofen
ketoprofen–β-cyclodextrin
complex
with
enhanced
properties.
The
objective
was
improve
inflammation
management
outcomes
using
novel
delivery
system
based
on
the
inclusion
of
active
substance
in
cyclodextrin
complexes.
Methods:
Tablets
were
formulated
complexes
combined
hydrophilic
polymers
such
as
Carbopol®
971P
NF,
Kollidon®
VA
64,
MethocelTM
K4M.
obtained
via
coprecipitation
method
bioavailability.
kinetics
release
ketoprofen,
(2:1),
(1:1)
from
tablets
investigated
vitro
artificial
gastric
intestinal
fluids,
drug
profiles
established.
Advanced
mathematical
models
used
describe
nonlinear
behavior
drug–polymer
systems.
Results:
β-cyclodextrin
confirmed,
revealing
distinct
profiles.
(K-3
F-3)
1:1
showed
rapid
(96.2%
4–7
h),
while
(K-1
F-4)
free
released
76%
over
9–11
h.
Higher
concentrations
slowed
due
gel
barrier
formation.
Pharmacotechnical
stability
tests
supported
their
suitability
forms.
A
multifractal
modeling
approach
described
dynamics,
treating
polymer–drug
system,
curves
characterized
variations
fractal
dimension
resolution.
Conclusions:
Specific
combinations
effectively
prolonged
release.
developed
tablets,
which
evaluated
studies
modeling,
show
promise
for
improving
patient
compliance
during
rheumatoid
Research Journal of Pharmacy and Technology,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1118 - 1127
Published: March 27, 2025
Rheumatoid
arthritis
(RA)
is
a
systemic
autoimmune
disorder
characterized
by
persistent
joint
inflammation,
leading
to
severe
disability
and
increased
mortality
rates.
Fenugreek,
known
for
its
anti-arthritic
effects,
demonstrates
promise
in
retarding
RA
onset
progression.
However,
challenges
like
poor
bioavailability
limited
target
specificity
hinder
therapeutic
utility.
To
circumvent
these
limitations,
transdermal
delivery
systems,
notably
transferosomes,
offer
viable
solution.
This
study
aimed
formulate
transferosomal
gel
incorporating
Trigonella
foenum-graecum
(TFG)
extract,
employing
the
thin-film
hydration
technique.
Evaluation
parameters
encompassed
stability,
zeta
potential,
particle
size,
entrapment
efficiency,
deformability.
The
synthesized
transferosomes
were
integrated
into
Carbopol
enhance
ease
of
application
prolong
skin
retention.
Comparative
analyses
with
conventional
assessed
such
as
consistency,
transparency,
viscosity,
pH.
Experimental
findings
revealed
successful
TFG
extract
(63.69±3.20%
w/w)
within
exhibiting
favorable
size
(269.20±1.20nm)
deformability
(23.71±0.92).
Skin
penetration
kinetics
demonstrated
gradual
increase
concentration
over
time,
TFG-extract-loaded
highest
among
formulations
at
all-time
points.
stability
studies
indicated
prolonged
TFG-transferosomes
formulations.
In
conclusion,
developed
extract-loaded
presents
promising
strategy
improved
delivery,
offering
potential
benefits
management.
Panminerva Medica,
Journal Year:
2024,
Volume and Issue:
66(4)
Published: Dec. 2, 2024
Rheumatoid
arthritis
(RA)
is
an
autoimmune
inflammatory
condition
that
primarily
affects
the
joints
and
periarticular
soft
tissue.
The
development
of
joint
swelling
traditionally
regarded
as
starting
point
disease.
Emerging
evidence
indicates
RA
patients
often
experience
a
preclinical
stage
characterized
by
immunological
changes
before
developing
review
discusses
ongoing
efforts
to
predict
transition
from
this
phase
clinical
describes
studies
aimed
at
preventing
onset
in
individuals
risk.
Over
past
two
decades,
there
have
been
significant
advancements
management
outcomes.
An
increasing
number
can
now
achieve
disease
remission,
some
cases,
remission
persists
without
treatment,
which
effectively
cure.
As
new
therapies
evolving
scientific
emerge,
recommendations
for
are
continuously
evolving.
Despite
these
improvements
RA,
many
still
do
not
respond
multiple
conventional
or
more
advanced
therapies,
including
biologic
targeted
synthetic
modifying
anti-rheumatic
drugs,
flares
when
treatments
tapered
discontinued.
This
situation
underscores
need
reliable
biomarkers
guide
therapy
effectively,
improve
personalized
treatment
approaches
monitoring
strategies
(i.e.
precision
medicine).
In
conclusion,
provides
comprehensive
overview
covering
research
on
'pre-clinical'
disease,
well
its
epidemiology,
pathogenesis,
manifestations,
diagnosis,
imaging,
strategies.
It
highlights
key
aspects
addresses
challenges
management,
particularly
areas
prevention
treatment.
